Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet.
“CAR-T cell therapy is a type of immunotherapy that involves harnessing the power of a person’s own immune system by engineering their T cells to recognize and destroy cancer cells,” says Yi Lin, M.D., a Mayo Clinic hematologist and lead author of the study.
